Perifosine (KRX-0401)是一种新型的Akt抑制剂,IC50为4.7 μM,靶向作用于Akt的pleckstrin homology (PH)区。
Perifosine is a synthetic antitumor alkylphospholipid. It induces cell apoptosis through inhibiting the activity of Akt. Perifosine shows antitumor activity in various cell lines including NSCLC, MM, epithelial carcinoma, prostate carcinoma and leukemia cells. In H460 cells, perifosine decreased cell survival and induced apoptosis with IC50 values of 1μM and 10 μM, respectively. The treatment of perifosine was also found to induce cleavage of caspase-8, caspase-9, caspase-3 and PARP in this cell line. In MM.1S cells, perifosine induced sub-G1 phase population increase from 15% to 57% at 10 μM and induced cleavage of caspase-8, caspase-9 and PARP in a dose-dependent manner. In mice inoculated with MM.1S cells, oral administration of perifosine significantly reduced MM tumor growth and increased survival.
30% Propylene glycol, 5% Tween 80, 65% D5W(5%葡萄糖水溶液)
0, 15, 30,45 μM
250 mg/kg/wk或者36 mg/kg/d 口服
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Vyomesh Patel, et al. Cancer Res, 2002, 62(5), 1401-1409.
[2] Fu et al (2009) Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res. 69 8967.
[3] Tazzari et al (2008) Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res. 68 9394.
[4] Delgado-Ramírez et al (2016) Modulation of the voltage-gated potassium channel Kv2.1 by the anti-tumor alkylphospholipid perifosine. Pharmacol Rep. 68 457.
分子式 C25H52NO4P |
分子量 461.66 |
CAS号 157716-52-4 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO <1 mg/mL |
Water 8 mg/mL |
Ethanol 15 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00590954 | Malignant Gliomas|CNS|Brain Cancer|Cancer | Drug: Perifosine | Memorial Sloan Kettering Cancer Center|Keryx Biopharmaceuticals|Keryx / AOI Pharmaceuticals, Inc.|Online Collaborative Oncology Group|University of Wisconsin, Madison|Columbia University | Phase 2 | 2006-05-01 | 2016-06-01 |
NCT01049841 | Pediatric Solid Tumors | Drug: perifosine + temsirolimus | Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris | Phase 1 | 2010-01-01 | 2017-03-09 |
NCT00873457 | Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma | Drug: perifosine | Daphne Friedman|Keryx Biopharmaceuticals|Keryx / AOI Pharmaceuticals, Inc.|Duke University | Phase 2 | 2009-08-01 | 2013-05-19 |
NCT00422656 | Waldenstrom's Macroglobulinemia | Drug: Perifosine | Dana-Farber Cancer Institute | Phase 2 | 2006-09-01 | 2013-10-16 |
NCT00398879 | Colon Cancer | Drug: Perifosine in combination with capecitabine | AEterna Zentaris | Phase 2 | 2005-08-01 | 2013-03-04 |
NCT00498966 | Kidney Cancer | Drug: Perifosine | AEterna Zentaris | Phase 2 | 2007-07-01 | 2014-02-14 |
NCT01224730 | Cancer | Drug: perifosine | AEterna Zentaris | Phase 1 | 2012-01-01 | 2012-05-30 |
NCT00776867 | Solid Tumors | Drug: perifosine | Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|AEterna Zentaris | Phase 1 | 2008-10-01 | 2016-09-19 |
NCT00391560 | Leukemia | Drug: perifosine | AEterna Zentaris | Phase 2 | 2006-10-01 | 2013-03-04 |
NCT00399789 | Non Small Cell Lung Cancer | Drug: Perifosine | AEterna Zentaris | Phase 1|Phase 2 | 2004-09-01 | 2014-02-11 |
NCT00455559 | Gastrointestinal Stromal Tumors | Drug: Perifosine|Drug: Imatinib Mesylate | AEterna Zentaris|M.D. Anderson Cancer Center | Phase 2 | 2006-08-01 | 2014-02-14 |
NCT00448721 | Renal Cell Carcinoma | Drug: Perifosine | AEterna Zentaris|Dana-Farber Cancer Institute | Phase 2 | 2007-03-01 | 2014-02-11 |
NCT01048580 | Colon Cancer | Drug: Perifosine + Capecitabine | AEterna Zentaris|SCRI Development Innovations, LLC | Phase 1 | 2009-10-01 | 2014-02-14 |
NCT00375791 | Multiple Myeloma | Drug: perifosine|Drug: dexamethasone | AEterna Zentaris | Phase 2 | 2005-12-01 | 2014-02-11 |
NCT00389077 | Tumors|Lymphomas | Drug: Perifosine Daily Dose|Drug: Perifosine | AEterna Zentaris | Phase 2 | 2005-01-01 | 2014-02-12 |
NCT00058214 | Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer | Drug: perifosine|Other: laboratory biomarker analysis | National Cancer Institute (NCI) | Phase 2 | 2003-03-01 | 2015-02-09 |
NCT00847366 | Non Small Cell Lung Cancer|Solid Tumors|Metastatic Breast Cancer|Sarcomas | Drug: Perifosine|Drug: Perifosine|Drug: Perifosine|Drug: Perifosine|Drug: Perifosine | AEterna Zentaris | 2008-05-01 | 2012-05-28 | |
NCT00399152 | Renal Cancer|GIST | Drug: Perifosine|Drug: Sunitinib Malate | AEterna Zentaris | Phase 1 | 2006-10-01 | 2014-02-14 |
NCT00398814 | Renal Cancer|Tumors | Drug: Perifosine|Drug: Sorafenib | AEterna Zentaris | Phase 1 | 2006-10-01 | 2014-02-14 |
NCT01051557 | Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm | Other: Laboratory Biomarker Analysis|Drug: Perifosine|Drug: Temsirolimus|Procedure: Therapeutic Conventional Surgery | National Cancer Institute (NCI) | Phase 1|Phase 2 | 2010-01-01 | 2017-03-03 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们